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Endothelin receptors (ETA and ETB) are G-protein-coupled receptors activated by endothelin-
1 and are involved in blood pressure regulation. IRL2500 is a peptide-mimetic of the
C-terminal tripeptide of endothelin-1, and has been characterized as a potent ETB-selective
antagonist, which has preventive effects against brain edema. Here, we report the crystal
structure of the human ETB receptor in complex with IRL2500 at 2.7 Å-resolution. The
structure revealed the different binding modes between IRL2500 and endothelin-1, and
provides structural insights into its ETB-selectivity. Notably, the biphenyl group of IRL2500
penetrates into the transmembrane core proximal to D2.50, thus stabilizing the inactive
conformation. Using the newly-established constitutively active mutant, we clearly demon-
strate that IRL2500 functions as an inverse agonist for the ETB receptor. The current findings
will expand the chemical space of ETR antagonists and facilitate the design of inverse ago-
nists for other class A GPCRs.
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Endothelin receptors (ETRs) are G-protein-coupled receptors(GPCR) activated by vasoactive peptide, endothelins1. TwoETR subtypes (ETA and ETB) are widely expressed in the
vascular endothelium, brain, and other circulatory organs2,3.
Endothelin-1 (ET-1) activates the both ETRs with sub-nanomolar
affinities. The activation of the ETA receptor leads to potent and
long-lasting vasoconstriction, whereas that of the ETB receptor
induces nitric oxide-mediated vasorelaxation. Therefore, the up-
regulation of ET-1 is related to circulatory-system diseases,
including pulmonary arterial hypertension (PAH)4–7. Moreover,
the autocrine and paracrine signaling functions of ET-1 through
the ETA receptor play a critical role in tumor growth and survi-
val8. Thus, ETR antagonists have been developed for the treat-
ment of circulatory-system diseases and cancers6,7. Bosentan is
the first orally-active ETR antagonist9,10, and is used to treat
PAH. The ETB receptor is the prominent ETR subtype in the
brain, with high expression levels in astrocytes11. Stimulation of
the ETB receptor modulates astrocytic responses, indicating its
important roles in regulating astrocytic functions12. The up-
regulation of the astrocytic ETB receptor by ET-1 increases the
vascular permeability and reduces the AQP4 levels, thereby
aggravating vasogenic brain edema11. The application of ETB-
selective antagonists may provide preventive effects against brain
edema in the acute phase of brain insults13–16.
To date, most ETR antagonists have been developed based on
bosentan17,18. The ETR antagonists that have been developed till
now are mostly N-heterocyclic sulfonamides with similar struc-
tures and molecular weights, and non-sulfonamide antagonists
(atrasentan, ambrisentan, darusentan, and enrasentan) still retain
high similarities with each other and with the sulfonamides6.
Since the ETR antagonists are chemically very similar7, and the
expanded chemical space should be exploited. IRL2500 is a
peptide-mimetic ETR antagonist developed based on the par-
tial region of ET-119, not on bosentan. IRL2500 has been char-
acterized as an ETB-selective antagonist with an IC50 value of 1.2
nM20, which shows higher affinity than that of bosentan. In an
animal model, the intracerebroventricular administration of
IRL2500 attenuated the cold injury-mediated brain edema and
disruption of the blood–brain barrier, indicating the neuropro-
tective effect of IRL250014,15. Clarification of the IRL2500 binding
mode would facilitate the expansion of the chemical space of ET
agents.
We previously reported the crystal structures of the ETB
receptor bound to ET-121 and bosentan22; however, both the
binding mode and ETB-selectivity of IRL2500 remained to be
elucidated. Here, we present the crystal structure of the ETB
receptor in complex with IRL2500. This structure revealed the
unique binding mode of IRL2500, which differs from those of ET-
1 and bosentan. Structure-guided functional analyses clearly
demonstrate that IRL2500 functions as an inverse agonist for the
ETB receptor, and thus will provide the basis for the design of
inverse agonists for other class A GPCRs.
Results
Overall structure. For crystallization, we used the previously
established, thermostabilized ETB receptor (ETB-Y4)22,23. The
IC50 value of IRL2500 for ETB-Y4 was similar to that for the wild
type receptor in the TGFα shedding assay24 (Fig. 1a), suggesting
that the thermostabilizing mutations minimally affect the
IRL2500 binding. In contrast, the IC50 value of IRL2500 for the
ETA receptor is over 3 μM (Fig. 1a), indicating that IRL2500 has
over 100-fold ETB-selectivity, consistent with the previous phar-
macological analysis20. To facilitate crystallization, we replaced
the third intracellular loop (ICL3) of the receptor with minimal
T4 Lysozyme25 (ETB-Y4-mT4L). Using in meso crystallization26,
we obtained crystals of ETB-Y4-mT4L in complex with IRL2500
(Supplementary Fig. 1a, b). In total, 58 datasets were collected and
merged by the data processing system KAMO27. Eventually, we
determined the ETB structure in complex with IRL2500 at 2.7 Å
resolution, by molecular replacement using the antagonist-bound
ETB structure (PDB code: 5X93) (Table 1).
The overall structure consists of the canonical 7 transmem-
brane helices (TM), the amphipathic helix 8 at the C-terminus
(H8), and two antiparallel β-strands in the extracellular loop 2
(ECL2), as in the previously determined ETB structures (Fig. 1b).
The IRL2500-bound structure is similar to the bosentan-bound
structure, rather than the ET-1-bound structure (R.M.S.D. values
for Cα atoms= 1.34 and 1.95 Å, respectively), reflecting the
inactive conformation. We observed a remarkable difference in
the conformation of ECL2. The β strands are opened up by 9 Å,
as compared with those in the ligand-free structure (Fig. 1c and
Supplementary Fig. 2a), and are the widest among the peptide-
activated class A GPCRs (Supplementary Fig. 2b). This
conformation is facilitated by the crystal packing (Supplementary
Fig. 2c), and is not a consequence of IRL2500 binding. This
structural feature indicates the ECL2 is highly flexible in the
inactive conformation of the ETB receptor, to capture the large
peptide ligand endothelin.
IRL2500 binding site. We first describe the IRL2500 binding
mode. IRL2500 consists of a tryptophan, a biphenyl group and a
3,5-dimethylbenzoyl group19. The biphenyl group forms a pep-
tide bond with the tryptophan, and a peptoid bond with the
dimethylbenzoyl group (Fig. 1d). IRL2500 binds to the trans-
membrane binding cleft exposed to the extracellular side, with a
clear electron density (Supplementary Fig. 3a, b). The carboxylate
group of the tryptophan moiety in IRL2500 forms salt bridges
with R3436.55 (superscripts indicate Ballesteros–Weinstein num-
bers28) (Fig. 1e, f). The tryptophan side chain of IRL2500 forms a
hydrogen bond with the carbonyl group of the N1582.61 side
chain and a cation–π interaction with the K1612.64 side chain,
The tryptophan also forms extensive van der Waals interactions
with V1773.28, P1783.29, and F2404.64. The dimethylbenzoyl group
of IRL2500 forms van der Waals interactions with the hydro-
phobic pocket, and is surrounded by V1853.36, L2775.42, Y2815.46,
W3366.48 and L3396.51. The biphenyl group penetrates deeply
into the receptor core proximal to D1472.50, and forms van der
Waals interactions with D1472.50, H1502.53, W3366.48, and
S3767.43. Overall, the carboxylate of IRL2500 is specifically
recognized by the positively charged residues of the ETB receptor,
and the other moieties fill the space within the transmembrane
binding pocket.
To elucidate the structural basis for the ETB-selectivity of
IRL2500, we compared the residues constituting the IRL2500
binding site between the ETB and ETA receptors (Fig. 2a and
Supplementary Fig. 4). Most of the residues are conserved, while
H1502.53, V1773.28, and S3767.43 are substituted for the bulkier
residues Y1292.53, F1613.28, and T3597.43 in the ETA receptor,
respectively. These substitutions may cause steric clashes with the
aromatic groups of IRL2500 and reduce its affinity. To investigate
this hypothesis, we measured the IC50 values of IRL2500 for the
H150Y, V177F, and S376T ETB receptor mutants. These mutants
showed similar responses for ET-1 in the TGFα shedding assay
(Supplementary Fig. 5a). The H150Y mutant showed a similar
response for IRL2500, and the S376T mutant showed a 3-fold
increased potency (that is, 3-fold smaller IC50value) of IRL2500.
Only V177F showed a 6-fold decreased potency of IRL2500
(Fig. 2b and Table 2), suggesting that the F1613.28 in the ETA
receptor sterically clashes with the tryptophan moiety of IRL2500.
Moreover, the H150Y/V177F double mutant showed the further
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decreased potency of IRL2500 by about 1.5-fold as compared with
that of the V177F mutant only (Fig. 2b and Table 2), suggesting
that the two residues have some cooperativity in the ETA
receptor. Notably, these mutations did not reduce (actually
increased) the potency of the non-selective antagonist bosentan,
showing that the two residues (H150Y and V177F) were selective
to the IRL2500 inhibition. Taken together, Y1292.53 and F1613.28
in the ETA receptor may specifically clash with IRL2500, partially
accounting for its ETB-selectivity. This is consistent with the
results of the previous study, in which the replacement of the
tryptophan moiety with the smaller moiety valine weakened its
ETB-selectivity29.
Comparison of the binding modes of IRL2500, ET-1, and
bosentan. IRL2500 is designed to mimic the F14, I19, I20, and
W21 residues in ET-1, which play critical roles in ligand binding
to the ETB receptor19. The tryptophan and dimethylbenzoyl
groups of IRL2500 seem to be equivalent to W21 and I19 in ET-1,
respectively, while the biphenyl group of IRL2500 seems to be
equivalent to F14 and I20 of ET-1 (Fig. 3a). However, a com-
parison between the IRL2500 and ET-1 binding revealed an
unexpected difference in their binding interactions (Fig. 3b). The
carboxylate of the tryptophan in IRL2500 superimposes well with
that of W21 in ET-1, and is coordinated by similar positively
charged residues (Fig. 3c). The tryptophan of IRL2500 does not
superimpose with the W21 of ET-1, but do with the I20. Instead,
the dimethylbenzoyl group of IRL2500 superimposes with the
W21. Nevertheless, these hydrophobic moieties of IRL2500 and
ET-1 form comparable hydrophobic interactions (Fig. 3c, d). In
contrast, the biphenyl group of IRL2500 penetrates into the
receptor core, in an opposite manner to the F14 and I20 of ET-1
(Fig. 3b). Overall, while the electrostatic interactions between the
carboxylates and the positively charged residues are conserved in
IRL2500 and ET-1 binding, the other moieties form distinct
interactions with the receptor. The volume of the ligand binding
pocket in the ligand-free structure is large, thereby allowing the
aromatic moieties of IRL2500 to flip (Fig. 3b).
IRL2500 has distinct chemical moieties as compared with
bosentan, because IRL2500 was not developed based on bosentan.
To reveal the similarities and differences in their binding modes,
we compared the binding modes of IRL2500 and bosentan in
detail (Fig. 3e, f). The carboxylate of IRL2500 and the
sulfonamide of bosentan are similarly coordinated by the
positively charged residue R3436.55, suggesting that this electro-
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Fig. 1 Overall structure of the IRL2500-bound ETB receptor. a The effect of IRL2500 on the ET-1 (0.5 nM)-induced release of AP-TGFα in HEK293 cells
expressing the endothelin receptors. For each experiment, the AP-TGFα release response in the absence of IRL2500 is set at 100%. Concentration-
response data are displayed as means ± SEM (standard error of the mean) from six to thirteen independent experiments and the pIC50 values are from the
indicated number of independent experiments. b The overall structure of the IRL2500-bound ETB receptor. The receptor is shown as a sky blue ribbon
model. IRL2500 is shown as a deep sky blue stick model with a transparent surface model. c Superimposition of the IRL2500-bound and ligand-free ETB
structures (PDB code: 5GLI), colored sky blue and light green, respectively. d Schematic representation of the interactions between ETB and IRL2500 within
4.5 Å. The dashed lines show hydrogen bonds. e, f Binding pocket for IRL2500, viewed from the membrane plane (e) and the extracellular side (f). The
receptor is shown in a sky blue ribbon representation. IRL2500 and receptor residues involved in ligand binding are shown as sticks, colored deep sky blue
and sky blue, respectively. The dashed lines show hydrogen bonds
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to the ETB receptor. In addition, like bosentan, the aromatic
moieties of IRL2500 fit within the local hydrophobic pockets in
the ETB receptor. Overall, IRL2500 has moieties that form similar
binding interactions to those of bosentan. However, bosentan
lacks the moiety corresponding to the biphenyl group of IRL2500,
which deeply penetrates into the receptor core (Fig. 3f). Thus,
IRL2500 fits into the pocket more tightly as compared with
bosentan, contributing to its higher affinity for the ETB receptor.
IRL2500 functions as an inverse agonist. To obtain mechanistic
insights into the receptor inactivation by IRL2500, we compared
the ETB structures bound to ET-1, bosentan, and IRL2500. Pre-
vious structural studies showed that ET-1 binding induces the
inward motion of the extracellular portion of TM6 including
W3366.48, leading to receptor activation on the intracellular side21
(Fig. 4a). Bosentan binding sterically prevents the inward motion
of W3366.48 with its 2-methoxyphenoxy group, and thus func-
tions as an antagonist22 (Fig. 4b). The dimethylbenzoyl group of
IRL2500 superimposes well with the 2-methoxyphenoxy group of
bosentan and similarly prevents the inward motion (Fig. 4b).
Moreover, the dimethylbenzoyl and biphenyl groups of
IRL2500 sandwich the W3366.48 side chain, tightly preventing its
inward rotation (Fig. 4c). These observations suggest that
IRL2500 tightly prevents the transition to the active state, as
compared with bosentan, thereby possibly working as an inverse
agonist that reduces the basal activity.
To investigate the inverse agonist activity of IRL2500 for the
ETB receptor, we first measured the ligand-induced AP-TGFα
release responses. In the wild-type ETB, treatment with IRL2500
or the antagonist bosentan with the cells for 4 h-incubation did
not change the receptor activation level (Fig. 4d and Table 3).
These data suggested that IRL2500 either does not have the
inverse agonist activity or that the assay is not sensitive enough to
detect the inverse agonist activity. Indeed, we observed that the
basal activity of the ETB receptor was very low in the assay and
thus we could not distinguish whether IRL2500 functions as an
antagonist or an inverse agonist by this assay.
Therefore, we tried the same assay by utilizing a mutation to
facilitate the constitutive activity of the ETB receptor. Constitu-
tively active mutant GPCRs have been employed in pharmaco-
logical characterizations of inverse agonists30, because such
mutant GPCRs allow the signal measurement in a larger detection
window. The substitution of the highly conserved L3.43 to
glutamine has been identified as a causative activating mutation
in the TSHR31 and CYSLTR232 genes, which are related to
hyperthyroidism and uveal melanoma, respectively. Therefore, we
transferred the L3.43Q mutation into the ETB receptor (ETB-
L1923.43Q) and examined its constitutive activity. We found that
ETB-L3.43Q induced spontaneous AP-TGFα release (Fig. 4e),
indicating that L3.43Q functions as a constitutively active
mutation in the ETB receptor. We confirmed that this mutation
also increased the constitutive activity in the ETA receptor
(Supplementary Fig. 6a). The L3.43Q-mutant ETB and ETA
increased the potency of both ET-1 (EC50) and the antagonists
(IC50) by approximately 5-fold and 2-fold, respectively (Supple-
mentary Fig. 5b–d). We evaluated the inverse agonist activities of
these compounds, using the constitutively active mutant, ETB-
L3.43Q (Fig. 4f and Table 3). As expected, the antagonist bosentan
did not change the receptor activation from the baseline level.
Conversely, IRL2500 reduced the basal activity of the ETB-L3.43Q
mutant (EC50= 0.92 nM). Both bosentan and IRL2500 did not
change the basal activity of the ETA-L3.43Q (Supplementary Fig.
6b, c). These data indicate that IRL2500 functions as a potent
inverse agonist for the ETB receptor, consistent with the structural
observations. The biphenyl group of IRL2500 prevents the inward
motion of W3366.48 to stabilize the inactive conformation, and
thus IRL2500 functions as an inverse agonist.
In addition to IRL2500, K-8794 and BQ-788 have been
characterized as potent ETB-selective antagonists. K-8794 is a
high-affinity analog of bosentan22, whereas BQ-788 is a peptide
analog with distinct chemical moieties, as compared with those of
IRL2500 and bosentan33. We investigated the inverse agonist
activities of K-8794 and BQ-788, using the constitutively active
mutants of the ETRs (Fig. 4f and Table 3). K-8794 and BQ-788
reduced the basal activity of the ETB-L3.43Q with EC50 values of
0.61 and 0.96 nM, respectively, indicating that they also function
as inverse agonists. K-8794 and BQ-788 showed higher and lower
efficacies (Emax) of the inverse agonist activity than that
of IRL2500, respectively. The K-8794-bound ETB structure has
been determined and thus we compare the ETB structures bound
to K-8794, bosentan, and IRL2500. The chemical structure of K-
8794 is similar to that of bosentan, but K-8794 has a
dimethylphenyl group linked to the peptide bond. This
modification slightly displaces the overall position of K-8794,
thereby moving W3366.48 outward by the interactions with the 6-
methoxyphenoxy and the alkyl groups (Supplementary Fig. 7a).
Therefore, K-8794 tightly prevents the inward rotation of
W3366.48, in a similar manner to IRL2500 (Supplementary
Fig. 7b). We thus suggest that this structural feature likely
contributes to the inverse agonist activity of K-8794.
Discussion
We have determined the crystal structure of the ETB receptor in
complex with the peptide-mimetic drug IRL2500, and thus elu-
cidated the detailed receptor interactions and the structural basis
for its ETB selectivity. Although IRL2500 is designed to mimic the
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partial region of ET-1, its binding mode is quite different.
Moreover, using the constitutively active mutant ETB-L3.43Q, we
revealed that IRL2500 together with K-8794 and BQ-788, but not
bosentan, function as a potent inverse agonist for the ETB
receptor, and provided the structural basis for their inverse ago-
nist activities. Our study sheds light on the new aspects of the
ETB-selective antagonists, and deepens our understanding of ETR
pharmacology.
Although small-molecule ETR antagonists have been devel-
oped over the years; however, most ETR antagonists have been
designed based on bosentan. Thus, the presently available ETR
antagonists are chemically very similar. IRL2500 was developed
based on ET-1 and has totally distinct chemical moieties, as
compared with those of bosentan. However, the comparison of
the IRL2500 and bosentan binding modes revealed the unex-
pected similarity in their binding interactions. This observation
suggests that the charge-complementary interactions in the center
of the pocket form the core of the receptor–antagonist interac-
tions, and the other aromatic moieties fit the local hydrophobic
pocket. The ligand binding pocket in the inactive ETB structures
is larger than those in other GPCR structures, and thus aromatic
moieties may be necessary to fit well within the pocket.
Our study revealed that the biphenyl group of IRL2500 pene-
trates deeply into the receptor core proximal to D1472.50, pre-
venting the inward motion of W3366.48 in TM6, and thus
IRL2500 functions as an inverse agonist (Fig. 5a, b). The deep
binding modes of the inverse agonists are also observed in the 5-
HT2CR and BLT1 structures (Fig. 5c–f). In the 5-HT2CR struc-
ture, the 4-fluorophenyl group of the inverse agonist ritanserin
interacts with F3206.44 and W3246.48, the purported “toggle
switch” important for GPCR activation34 (Fig. 5c, d). In the
































































































































Fig. 2 Conservation of the IRL2500 binding site. a Sequence conservation of the IRL2500 binding site between ETA and ETB, mapped onto the IRL2500-
bound structure. Conserved and non-conserved residues are colored sky blue and gray, respectively. The receptor residues involved in IRL2500 binding are
shown as sticks. The dashed lines show hydrogen bonds. b Effects of IRL2500 and bosentan on the ET-1 (0.5 nM)-induced release of AP-TGFα in HEK293
cells expressing the mutant ETB receptors. For each experiment, the AP-TGFα release response in the absence of IRL2500 is set at 100%. Data are
displayed as means ± SEM (standard error of the mean) from four to six independent experiments
Table 2 Pharmacological characterization of mutant ETB receptors
ETB--WT H150Y V177F S376T H150/V177F
n 6 4 4 4 4
ET-1 EC50 (nM) 0.14 0.090 0.093 0.16 0.11
pEC50 (mean ± SEM) 9.85 ± 0.07 10.05 ± 0.10 10.03 ± 0.11 9.79 ± 0.04 9.97 ± 0.08
IRL2500 IC50 (nM) 21 18 130 6.1 180
pIC50 (mean ± SEM) 7.67 ± 0.09 7.74 ± 0.15 6.87 ± 0.13 8.22 ± 0.15 6.75 ± 0.15
KB (nM) 2.4 0.78 7.8 0.63 12
pKB (mean ± SEM) 8.62 ± 0.07 9.11 ± 0.12 8.11 ± 0.07 9.20 ± 0.08 7.93 ± 0.14
ΔKB 1 3.0 0.30 4.0 0.20
ΔpKB (mean ± SEM) 0 0.47 ± 0.11 −0.53 ± 0.06 0.60 ± 0.03 -0.70 ± 0.14
Bosentan IC50 (nM) 3,300 270 1100 680 270
pIC50 (mean ± SEM) 5.48 ± 0.11 6.57 ± 0.05 5.97 ± 0.11 6.17 ± 0.16 6.56 ± 0.11
KB (nM) 400 12 70 71 17
pKB (mean ± SEM) 6.39 ± 0.09 7.92 ± 0.13 7.16 ± 0.05 7.15 ± 0.10 7.78 ± 0.02
ΔKB 1 35 6.1 5.8 26
ΔpKB (mean ± SEM) 0 1.55 ± 0.12 0.79 ± 0.08 0.76 ± 0.11 1.41 ± 0.06
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Fig. 3 Comparison of binding modes of IRL2500, ET-1, and bosentan. a Chemical structures of IRL2500 and the C-terminal tripeptide of ET-1. b
Superimposition of the IRL2500- and ET-1-bound ETB receptors (PDB code: 5GLH). The ET-1- and IRL2500-bound receptors are shown as pink and sky
blue ribbons, respectively. IRL2500 is shown as a stick model. ET-1 is shown as a magenta ribbon with stick models of the peptide residues (Y13, F14, I19,
I20, and W21). c, d The residues interacting with both IRL2500 and ET-1 are shown as sticks. e, f Binding pockets for bosentan (e) and IRL2500 (f), viewed
from the membrane plane. The bosentan-bound receptor (PDB code: 5XPR) is shown as a thin orange ribbon model. The residues involved in bosentan
binding (D1542.57, Q1813.32, K1823.33, K2735.38, W3366.48 and R3436.55) and D1472.50 are shown as sticks. Bosentan is shown as an orange stick model.
IRL2500 and the IRL2500-bound receptor are colored as in panel (a). The residues involved in IRL2500 binding (N1582.61, K1823.33, R3436.55, D1472.50 and
W3366.48) are shown as sticks
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BIIL260 fits into a sodium binding pocket around D1472.50
(Fig. 5e, f), which is highly conserved among the class A
GPCRs35. Sodium selectively competes with agonist binding in
most class A GPCRs by stabilizing the inactive conformations,
and the sodium binding site is thus an important pocket targeted
in the design of negative allosteric modulators and inverse ago-
nists. Instead of the sodium, the benzamidine group of BIIL260
directly hydrogen bonds with D2.50, similarly stabilizing the
inactive conformation36 (Fig. 5f). The binding mode of IRL2500
is similar to that of BIIL260 in BLT1, rather than that of ritan-
serin in the 5-HT2CR (Fig. 5g, h). Although the biphenyl group of
IRL2500 does not form any hydrogen-bonding interactions with
the receptor, it prevents the conformational change around the
D2.50 in a similar manner to the benzamidine moiety of BIIL260
(Fig. 5b, f). For the design of effective inverse agonists, the
biphenyl moiety would also be useful as a modulation part along
with another moiety that exerts specific and tight binding to the
orthosteric site, as well as a benzamidine group.
Methods
Expression and purification. The haemagglutinin signal peptide, followed by the
Flag epitope tag (DYKDDDDK) and a nine-amino-acid linker, was added to the N-
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Fig. 4 Inverse agonist activity of IRL2500. a, b Structural changes upon ET-1 and IRL2500 binding, as compared with the bosentan-bound structure, colored
as in Fig. 3. Black arrows indicate the inward movements of TM6 and W3366.48. c CPK representations of IRL2500 and the W3366.48 side chain. d Effects
of ET-1 and the ETB antagonists (bosentan, IRL2500, K-8794, and BQ-788) on the AP-TGFα release for the ETB receptor. For each experiment, the
spontaneous AP-TGFα release response in the absence of the compound is set at the baseline. Data are displayed as means ± SEM from
six to eleven independent experiments. e Constitutive activity of the L1923.43Q-mutant ETB receptor (ETB-L3.43Q). HEK293 cells were transfected with
titrated volumes of a plasmid encoding the wild-type ETB (ETB-WT) or the L3.43Q-mutant ETB (ETB-L3.43Q) and accumulated AP-TGFα release during 24 h
after transfection was measured. The AP-TGFα release signal in the 0 ng receptor plasmid was set as the baseline. Data are displayed as a box-and-whisker
plot from five independent experiments with each performed in 4–6 replicates. f Effects of ET-1 and the ETB antagonists (bosentan, IRL2500, K-8794 and
BQ-788) on the AP-TGFα release for the constitutively active ETB receptor (ETB-L3.43Q). For each experiment, the spontaneous AP-TGFα release response
in the absence of the compound is set at the baseline. Data are displayed as means ± SEM from seven to twelve independent experiments. In the inverse
agonist experiments (d, f), the cells were incubated with a test compound for 4 h




EC50 (nM) 0.19 0.094
pEC50 (mean ± SEM) 9.72 ± 0.03 10.03 ± 0.04
Emax ± SEM 53.6 ± 1.7 20.5 ± 1.3
n 10 12
Bosentan
EC50 (nM) NA NA
pEC50 (mean ± SEM) NA NA
Emax ± SEM <2% <2%
n 11 12
IRL2500
EC50 (nM) NA 0.92
pEC50 (mean ± SEM) NA 9.03 ± 0.05
Emax ± SEM <2% −27.0 ± 1.1
n 11 12
K-8794
EC50 (nM) NA 0.61
pEC50 (mean ± SEM) NA 9.21 ± 0.04
Emax ± SEM <2% −31.5 ± 2.0
n 6 7
BQ-788
EC50 (nM) NA 0.96
pEC50 (mean ± SEM) NA 9.02 ± 0.03
Emax ± SEM <2% −18.5 ± 0.7
n 6 7
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sequence was introduced between G57 and L66, to remove the disordered N-
terminus during the purification process. The C-terminus was truncated after S407,
and three cysteine residues were mutated to alanine (C396A, C400A, and C405A)
to avoid heterogeneous palmitoylation. To improve crystallogenesis, we introduced
four thermostabilizing mutations (R124Y1.55, K270A5.35, S342A6.54, and I381A7.48)
and inserted minimal T4 lysozyme25 into intracellular loop 3, between K3035.68
and L3116.23 (ETB-Y4-mT4L22).
The thermostabilized construct ETB-Y4-mT4L was subcloned into a modified
pFastBac vector, with the resulting construct encoding a TEV cleavage site followed







































Fig. 5 Structural comparison with the inverse agonist-bound GPCR structures. a–f The structures of the IRL2500-bound ETB receptor (a, b), Ritanserin-
bound 5-HT2CR (PDB code: 6BQH) (c, d), and the BIIL260-bound BLT1 (PDB code: 5X33) (e, f), shown as sky blue, purple and light green ribbons,
respectively. The inverse agonists IRL2500, ritanserin, and BIIL260 are shown as sticks. The binding interactions around the sodium binding site are shown
in (b), (d), and (f). The residues involved in ligand binding are represented with sticks. Hydrogen bonds are indicated by black dashed lines. In the IRL2500-
bound ETB structure, the biphenyl group of IRL2500 forms van der Waals interactions with the receptor, and does not form any hydrogen-binding
interactions. In the BIIL260-bound BLT1 structure, BIIL260 forms hydrogen bonds with D662.50, S1063.39 and S2767.45. g, h Superimposition of the
IRL2500-bound ETB structure with the BLT1 (g) and 5-HT2CR (h) structures
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using the Bac-to-Bac baculovirus expression system (Invitrogen). Sf9 insect cells
were infected with the virus at a cell density of 4.0 × 106 cells per ml in Sf900 II
medium, and grown for 48 h at 27 °C. The harvested cells were disrupted by
sonication, in buffer containing 20 mM Tris–HCl, pH 7.5, and 20% glycerol. The
crude membrane fraction was collected by ultracentrifugation at 180,000 g for 1 h.
The membrane fraction was solubilized in buffer, containing 20 mM Tris–HCl, pH
7.5, 200 mM NaCl, 1% DDM, 0.2% cholesterol hemisuccinate, 10 μM IRL2500, and
2 mgml−1 iodoacetamide, for 1 h at 4 °C. The supernatant was separated from the
insoluble material by ultracentrifugation at 180,000 g for 20 min, and incubated
with TALON resin (Clontech) for 30 min. The resin was washed with ten column
volumes of buffer, containing 20 mM Tris–HCl, pH 7.5, 500 mM NaCl, 0.1%
LMNG, 0.01% CHS, 10 μM IRL2500, and 15 mM imidazole. The receptor was
eluted in buffer, containing 20 mM Tris–HCl, pH 7.5, 500 mM NaCl, 0.01%
LMNG, 0.001% CHS, 10 μM IRL2500, and 200 mM imidazole. The eluate was
treated with TEV protease and dialyzed against buffer (20 mM Tris–HCl, pH 7.5,
500 mM NaCl, and 10 μM IRL2500). The cleaved GFP-His10 tag and the TEV
protease were removed with Co2+-NTA resin. The receptor was concentrated and
loaded onto a Superdex200 10/300 Increase size-exclusion column, equilibrated in
buffer containing 20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.01% LMNG, 0.001%
CHS, and 10 μM IRL2500. Peak fractions were pooled, concentrated to 40 mgml−1
using a centrifugal filter device (Millipore 50 kDaMW cutoff), and frozen until
crystallization. During the concentration, IRL2500 was added to a final
concentration of 100 μM.
Crystallization. The purified receptor was reconstituted into molten lipid (monoolein
and cholesterol 10:1 by mass) at a weight ratio of 1:1.5 (protein:lipid)37. The protein-
laden mesophase was dispensed into 96-well glass plates in 30 nl drops and overlaid
with 800 nl precipitant solution by a Gryphon LCP robot (Art Robbins Instruments)26.
Crystals of ETB-Y4-mT4L bound to IRL2500 were grown at 20 °C in precipitant
conditions containing 30% PEG300, 100mM Bis–tris, pH 7.5, 150mM sodium
phosphate monobasic, and 10mM TCEP hydrochloride. The crystals were harvested
directly from the LCP using micromounts (MiTeGen) or LithoLoops (Protein Wave)
and frozen in liquid nitrogen, without adding any extra cryoprotectant.
Data collection and structure determination. X-ray diffraction data were col-
lected at the SPring-8 beamline BL32XU, with 10 × 15 μm2 (width × height) micro-
focused beams and an EIGER X 9M detector (Dectris). Various wedge data sets
(10°) per crystal were mainly collected with the ZOO system38, an automatic data-
collection system developed at SPring-8. The loop-harvested microcrystals were
identified by raster scanning and subsequently analyzed by SHIKA39. The collected
images were automatically processed with KAMO40 (https://github.com/
keitaroyam/yamtbx). Each data set was indexed and integrated with XDS41, and the
datasets were hierarchically clustered by using the correlation coefficients of the
intensities between datasets41. After the rejection of outliers, 58 data sets were
finally merged with XSCALE41. The IRL2500-bound structure was determined by
molecular replacement with PHASER42, using the K-8794-bound ETB structure
(PDB code: 5X93). Subsequently, the model was rebuilt and refined using COOT43
and PHENIX44, respectively. The final model of IRL2500-bound ETB-Y4-T4L
contained residues 91-207, 214-303, and 311-403 of ETB, 1-11 and 19-117 of
mT4L, IRL2500, 8 monoolein molecules, 4 phosphoric acids, and 34 water mole-
cules. The model quality was assessed by MolProbity45. Figures were prepared
using CueMol (http://www.cuemol.org/ja/).
TGFα shedding assay. The TGFα shedding assay, which measures the activation
of Gq/11 and G12/13 signaling24, was performed as described previously22. Briefly, a
plasmid encoding an ETB construct with an internal FLAG epitope tag or an ETA
construct was transfected, together with a plasmid encoding alkaline phosphatase
(AP)-tagged TGFα (AP-TGFα), into HEK293A cells by using a polyethylenimine
(PEI) transfection reagent (1 µg ETR plasmid, 2.5 µg AP-TGFα plasmid, and 25 µl
of 1 mg per ml PEI solution per 10-cm culture dish). After a 1-day culture, the
transfected cells were harvested by trypsinization, washed, and resuspended in 30
ml of Hank’s Balanced Salt Solution (HBSS) containing 5 mM HEPES (pH 7.4).
The cell suspension was seeded in a 96-well plate (cell plate) at a volume of 80 μl
per well and incubated for 30 min in a CO2 incubator. For the measurement of
antagonist activity, IRL2500 was diluted in 0.01% bovine serum albumin (BSA) and
HEPES-containing HBSS (assay buffer) and added to the cell plate at a volume of
10 µl per well. After 5 min, ET-1, at a final concentration of 0.5 nM, was added to
the cell plate at a volume of 10 µl per well. For the measurement of agonistic
activity, after adding 10 µl of the assay buffer, serially diluted ET-1 was mixed with
the cells at a volume of 10 µl per well. After a 1 h incubation in the CO2 incubator,
aliquots of the conditioned media (80 μl) were transferred to an empty 96-well
plate (conditioned media (CM) plate). Similarly, for the measurement of inverse
agonist activity, the cells were mixed with 10 µl of the assay buffer, followed by the
addition of serially diluted IRL2500, and incubated for 4 h before the transfer of the
conditioned media. The AP reaction solution (10 mM p-nitrophenylphosphate (p-
NPP), 120 mM Tris–HCl (pH 9.5), 40 mM NaCl, and 10 mM MgCl2) was dis-
pensed into the cell plates and the CM plates (80 µl per well). The absorbance at
405 nm (Abs405) of the plates was measured, using a microplate reader (Spec-
traMax 340 PC384, Molecular Devices), before and after a 1 h incubation at room
temperature. AP-TGFα release was calculated as described previously22. The AP-
TGFα release signals were fitted to a four-parameter sigmoidal concentration-
response curve, using the Prism 7 software (GraphPad Prism), and the pEC50
(equal to −log10 EC50) and Emax values were obtained.
To obtain equilibrium dissociation constant (KB), for each experiment
performed in parallel, IC50 values (IRL2500, K-8794, BQ-788), an EC50 value (ET-





The resulting KB values were logarithmically transformed and their negative
values (pKB) were used to calculate a difference in pKB value (ΔpKB) for a mutant
(MT) receptor as follows by using pKB value for WT receptor performed in parallel:
ΔpKB ¼ pKB MTð Þ  pKB WTð Þ
The pKB and the ΔpKB values were used to calculate mean and SEM.
To measure the constitutive activity in a plasmid volume-dependent manner,
HEK293 cells were seeded in a 96-well plate at a concentration of 4 × 105 cells per
ml in Opti-MEM I Reduced Serum Media (Thermo Fisher Scientific), in a volume
of 80 μl per well. A transfection mixture was prepared by mixing the PEI
transfection reagent (0.2 µl per well) and plasmids (20 ng AP-TGFα plasmid,
titrated ETR plasmid, and an empty vector to balance the total plasmid volume) in
Opti-MEM I Reduced Serum Media (20 µl). The mixture was added to the cells,
which were then incubated for 24 h before the transfer of the conditioned media.
After adding the AP reaction solution, the absorbances of the cells and the CM
plates were measured at 20 min intervals. The AP-TGFα release signals were
calculated as described above, and the signal in the mock-transfected conditions
was set at the baseline. A glutamine mutation was introduced into the internal
FLAG epitope-tagged ETB and the ETA constructs at L1923.43 and L1763.43,
respectively.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Coordinates and structure factors have been deposited in the Protein Data Bank, under
the accession number 6K1Q for the IRL2500-bound structure. The raw X-ray diffraction
images are also available at Zenodo (https://zenodo.org/record/2803553). All other data
are available from the authors upon reasonable request.
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